Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

J Hepatol. 1999 Jan;30(1):156-60. Unique Identifier : AIDSLINE MED/99124353
Chariot P; Drogou I; de Lacroix-Szmania I; Eliezer-Vanerot MC; Chazaud B; Lombes A; Schaeffer A; Zafrani ES; Department of Pathology, Hopital Henri Mondor, Groupe d'Etudes; et de Recherches sur le Muscle et le Nerf (EA 2347, Universite; Paris XII), Faculte de Medecine, Creteil, France.

Abstract: Zidovudine is known to be responsible for a mitochondrial myopathy with ragged-red fibres and mitochondrial DNA depletion in muscle. Lactic acidosis alone or associated with hepatic abnormalities has also been reported. A single report mentioned the concomitant occurrence of muscular and hepatic disturbances and lactic acidosis in a patient receiving zidovudine, but muscle and liver tissues were not studied. A 57-year-old man with AIDS, who had been treated with zidovudine for 3 years, developed fatigue and weight loss. Serum creatine kinase and hepatic enzyme levels were high. Lactic acidosis was present. Liver biopsy showed diffuse macrovacuolar and microvacuolar steatosis. After withdrawal of zidovudine, creatine kinase, aspartate aminotransferase, and alanine aminotransferase levels normalised within 5 days, and lactacidaemia decreased. Acidosis persisted. The patient became confused and febrile and died 8 days after detection of high blood lactic acid. A muscle sample obtained at autopsy showed mitochondrial abnormalities with ragged-red fibres and lipid droplet accumulation. Southern blot analysis showed depletion of mitochondrial DNA, affecting skeletal muscle and liver tissue. No depletion was found in myocardium and kidney. This case emphasises that zidovudine treatment can induce mitochondrial multisystem disease, as revealed in our case by myopathy, liver steatosis and lactic acidosis.

Keywords: JOURNAL ARTICLE Acidosis, Lactic/*CHEMICALLY INDUCED Acquired Immunodeficiency Syndrome/DRUG THERAPY Anti-HIV Agents/*ADVERSE EFFECTS Case Report DNA, Mitochondrial/*DRUG EFFECTS/METABOLISM Fatty Liver/*CHEMICALLY INDUCED/PATHOLOGY Human Liver/PATHOLOGY Male Middle Age Mitochondria, Liver/*DRUG EFFECTS Muscle, Skeletal/PATHOLOGY Muscular Diseases/*CHEMICALLY INDUCED/PATHOLOGY Support, Non-U.S. Gov't Zidovudine/*ADVERSE EFFECTS
990630
A9960584

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .